Date	Event	Description
16 October 2018	New citation required and conclusions have changed	For people with familial Mediterranean fever who are colchicine‐resistant anakinra might be effective. For children with familial Mediterranean fever, there does not seem to be any difference between single or split doses of colchicine.
16 October 2018	New search has been performed	A new intervention of canakinumab was added to the review and consequently the search strategy was amended; a new search was performed. A total of 76 new reports were identified (after duplicates removed). One new study was included (Polat 2016). Six new studies (with one reference each) were added to 'Excluded studies' (Brik 2014; Demirkaya 2016; Gül 2015; Haviv 2016; Ozdogan 2017; Uguztemur 2017). One study previously listed as an 'Ongoing study' was included in the current review version (Ben‐Zvi 2017). Two studies previously listed as 'Awaiting classification' have now been included (Dinarello 1974; Wright 1977). One study of colchicine dose frequency which was previously listed as 'Excluded studies' has now been included after clarification that such comparisons are eligible (Kosan 2004). One new study has been listed as ongoing (NCT03446209). One study, with one full published article and four conference abstracts, has been listed as 'Awaiting classification' (De Benedetti 2018). "Prevention of AA amyloidosis" was added as a primary outcome and 'Adverse events' moved to secondary outcomes.